Other Clinical Trial - Veno-venous Extracorporeal CO2 Removal in

Status Completed

Clinical Trial Summary

Hypothesis: Extracorporeal removal of CO2 can treat hypercapnia and respiratory acidosis, which allows application of lung protective ventilation. This downgrading of mechanical ventilation promotes better and more quickly lung recovery. Aim: The aim of the study is to treat respiratory acidosis and to reduce plateau pressures by using an extracorporeal removal of CO2 (ECCO2-R). This prospective study will include 10 patients with an Acute Respiratory Distress Syndrome (ARDS). ARDS is an inflammatory response in the lungs, the onset is acute with pulmonary oedema and shows bilateral densities on chest radiography. The take up of oxygen and the loss of CO2 in the lungs are difficult. Moreover the patient's blood can become acidic due to too much CO2. To promote a better gas-exchange, the patient with ARDS will be mechanically ventilated. This can be aggressive and harmful for the lungs. With the use of an extra-corporeal CO2-remover, CO2 can be removed so that the mechanical ventilation setting will be less aggressive and will decrease lesions in the lung. The veno-venous extracorporeal CO2-remover pumps blood from a vein via a catheter through an oxygenator (gas exchanger that adds oxygen to the blood and extracts carbon dioxide from the blood) and back into a vein. The investigators will use a standard dialysis catheter that will be put in a large vein. To prevent clotting of the system, the patient will receive heparin. In the study the investigators will work in periods of two hours, the situation before and after carbon dioxide removal will be compared. With this study the investigators want to prove that the CO2 in the blood decreases with at least 20 % with the use of the extracorporeal CO2 remover. More over the investigators want to prove that lower mechanical ventilation settings (thanks to CO2-removal by the ECCO2-R) will produce fewer lesions to the lungs.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Acidosis
Acute Lung Injury
ACUTE RESPIRATORY DISTRESS SYNDROME
Respiratory Distress Syndrome
Respiratory Distress Syndrome, Newborn

Clinical Trial Details

NCT number	NCT01911533
Study type	Interventional
Source	University Hospital, Ghent
Contact
Status	Completed
Phase	N/A
Start date	February 20, 2014
Completion date	September 12, 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04384445` - Zofin (Organicell Flow) for Patients With COVID-19	Phase 1/Phase 2
Recruiting	`NCT05535543` - Change in the Phase III Slope of the Volumetric Capnography by Prone Positioning in Acute Respiratory Distress Syndrome
Completed	`NCT04695392` - Restore Resilience in Critically Ill Children	N/A
Terminated	`NCT04972318` - Two Different Ventilatory Strategies in Acute Respiratory Distress Syndrome Due to Community-acquired Pneumonia	N/A
Completed	`NCT04534569` - Expert Panel Statement for the Respiratory Management of COVID-19 Related Acute Respiratory Failure (C-ARF)
Completed	`NCT04078984` - Driving Pressure as a Predictor of Mechanical Ventilation Weaning Time on Post-ARDS Patients in Pressure Support Ventilation.
Completed	`NCT04451291` - Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure	N/A
Not yet recruiting	`NCT06254313` - The Role of Cxcr4Hi neutrOPhils in InflueNza
Not yet recruiting	`NCT04798716` - The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19	Phase 1/Phase 2
Withdrawn	`NCT04909879` - Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome	Phase 2
Terminated	`NCT02867228` - Noninvasive Estimation of Work of Breathing	N/A
Not yet recruiting	`NCT02881385` - Effects on Respiratory Patterns and Patient-ventilator Synchrony Using Pressure Support Ventilation	N/A
Completed	`NCT02545621` - A Role for RAGE/TXNIP/Inflammasome Axis in Alveolar Macrophage Activation During ARDS (RIAMA): a Proof-of-concept Clinical Study
Withdrawn	`NCT02253667` - Palliative Use of High-flow Oxygen Nasal Cannula in End-of-life Lung Disease Patients	N/A
Completed	`NCT02232841` - Electrical Impedance Imaging of Patients on Mechanical Ventilation	N/A
Completed	`NCT02889770` - Dead Space Monitoring With Volumetric Capnography in ARDS Patients	N/A
Completed	`NCT01504893` - Very Low Tidal Volume vs Conventional Ventilatory Strategy for One-lung Ventilation in Thoracic Anesthesia	N/A
Withdrawn	`NCT01927237` - Pulmonary Vascular Effects of Respiratory Rate & Carbon Dioxide	N/A
Completed	`NCT01680783` - Non-Invasive Ventilation Via a Helmet Device for Patients Respiratory Failure	N/A
Completed	`NCT02814994` - Respiratory System Compliance Guided VT in Moderate to Severe ARDS Patients	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Veno-venous Extracorporeal CO2 Removal in ARDS-patients to Treat Respiratory Acidosis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms